Blog

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine products, and CC Biotechnology Corporation, a leader in the design and manufacturing of wearable, pen and auto injectors, today announced they have entered into a development agreement to combine PharmaTher’s ketamine formulation with CCBIO’s Felice Dose wearable delivery device to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The Company expects to conduct clinical studies with its wearable ketamine delivery device in Q1-2023. Currently, ketamine is delivered predominately by intravenous (“IV”) and intramuscular (“IM”) means in…

On the fifth episode of the Psychedelic Invest Podcast, the CEO of Psygen, Danny Motyka joins to talk about manufacturing psychedelics at scale.  During the conversation, host Bruce Eckfedlt asks the hard-hitting questions we all want to know about the development and future accessibility of these medicines.  We hope you enjoy it. New episodes of the podcast are released weekly. Stay tuned and subscribe to be notified when a new episode is published. This podcast is available on Apple Podcasts, Spotify, Google Podcasts, and everywhere podcasts can be found. Transcription You’re listening to the psychedelic invest podcast where we speak…

Psychedelic Invest’s very own Adam Tubero digs into Mind Medicine’s ($MNMD) LSD program, Ibogaine, and the company’s Q1 2022 earnings report. Adam explains why his sentiment around MNMD has started to shift lately. Are you bullish or bearish? Leave your comments over on the Psychedelic Invest YouTube channel.

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The trial evaluated the proprietary combination of Clearmind’s proprietary psychedelic molecule MEAI and SciSparc’s CannAmide™ for treating alcohol consumption. “We are extremely pleased with these positive results that once again strengthen our belief in the…

Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders. Braxia Scientific is pleased to announce that Health Canada has approved the Company’s application to the Special Access Program (‘SAP’) to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder in Ontario, through its wholly owned subsidiary Canadian Rapid Treatment Centre of Excellence (CRTCE). While this is Braxia Scientific’s first psilocybin-assisted therapy treatment approval using Health Canada’s SAP, which was amended January 5th, 2022 to include access to psychedelic compounds on a case-by-case basis outside of…